Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Cell Lymphoma
Earlier this year, the FDA approved a new frontline option for patients with diffuse large B-cell lymphoma (DLBCL): the antibody-drug conjugate polatuzumab vedotin (Polivy) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP). Combination chemotherapy involving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) — and before that, CHOP alone — has been the established option […]
FDA OKs New Frontline Endometrial Cancer Regimen, First in Decades
The FDA approved the immune checkpoint inhibitor dostarlimab (Jemperli) plus chemotherapy as a frontline option for certain patients with advanced or recurrent endometrial cancer, the agency announced on Monday. For adults with primary advanced or recurrent endometrial cancer that is mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H), dostarlimab is now approved as part of a […]
Addressing Burnout in an Invisible Part of the Health Workforce
Much has been written about the burnout of frontline health workers during the COVID pandemic and what must be done to help them. But what about public health workers — those operating behind the scenes who are also navigating long hours and increased stress? Helping those workers is the idea behind the Public Health-Hope, Equity, […]
How We Reported on Nurse Rehabilitation Programs
The pandemic took a heavy toll on frontline healthcare workers, especially nurses, prompting our team to look into whether states would be prepared to handle a potential influx of nurses needing help with substance use disorders. Our reporting led us to alternative-to-discipline programs, which are charged with getting nurses back on the job while protecting […]